Atovaquone/Proguanil Therapy for Plasmodium falciparum and Plasmodium vivax Malaria in Indonesians Who Lack Clinical Immunity

Authors

• Mark D. Lacy, U.S. Naval Medical Research Unit # 2
• Jason D. Maguire, U.S. Naval Medical Research Unit # 2Follow
• Mazie J. Barcus, U.S. Naval Medical Research Unit # 2
• Judith Ling, Kaiser Permanente MidAtlantic
• Michael J. Bangs, U.S. Naval Medical Research Unit # 2
• Robert Gramzinski, U.S. Naval Medical Research Unit # 2
• Hasan Basri, U.S. Naval Medical Research Unit # 2
• Priyanto Sismadi, Ministry of Health
• Gerri B. Miller, GlaxoSmithKline
• Jeffrey D. Chulay, AlphaVax
• David J. Fryauff, Naval Medical Research CenterFollow
• Stephen L. Hoffman, Sanaria
• J. Kevin Baird, U.S. Naval Medical Research Unit # 2Follow

Date of this Version

2002

Citation

Published in Clinical Infectious Diseases (2002) 35: e92-5. DOI: 1058-4838/2002/3509-00E1

Abstract

Thirty-eight of 295 subjects participating in a randomized, double-blind, placebo-controlled trial of the efficacy of daily administration of atovaquone/proguanil for malaria prevention developed malaria at some time during the 20-week prophylaxis period. These subjects (3 atovaquone/proguanil recipients and 35 placebo recipients) were treated with 4 tablets of atovaquone/proguanil per day for 3 days. Atovaquone/proguanil provided safe, well-tolerated, and effective therapy for uncomplicated malaria in nonimmune Indonesians.